本文選題：糖尿病　切入點(diǎn)：型　出處：《中國(guó)糖尿病雜志》2016年08期 　論文類型：期刊論文

【摘要】：目的評(píng)估沙格列汀聯(lián)合二甲雙胍治療T2DM伴正常體重代謝性肥胖(MONW)患者的有效性,以及對(duì)體脂成分的影響。方法選取單用二甲雙胍12周但血糖控制不佳的、18.5≤BMI24kg/m~2的T2DM患者197例,且均符合MONW診斷標(biāo)準(zhǔn)。按照隨機(jī)數(shù)字法將研究對(duì)象分為沙格列汀組100例和格列吡嗪組97例。兩組均聯(lián)合二甲雙胍治療12周,觀察體脂率(BF),糖脂代謝指標(biāo)及炎癥指標(biāo)的變化。結(jié)果兩組HbA_1c較治療前降低[沙格列汀(8.37±0.75)%vs(7.25±0.62)%,格列吡嗪(8.42±0.78)%vs(7.27±0.72)%,P0.05];沙格列汀組低血糖發(fā)生率低于格列吡嗪組(3.0%vs29.9%,P0.01)。沙格列汀組WC[男(85.84±4.07)vs(84.08±4.53)cm,女(81.53±5.93)vs(79.09±4.91)cm]和BF[男(28.71±4.22)%vs(27.47±5.66)%,女(37.18±6.52)%vs(36.06±6.30)%]較治療前降低(P0.05);沙格列汀組治療后WC[男(86.94±4.20)vs(84.08±4.53)cm,女(83.48±5.51)vs(79.09±4.91)cm]和BF[男(30.70±5.72)%vs(27.47±5.66)%,女(39.36±7.23)%vs(36.06±6.30)%]均較格列吡嗪組降低(P0.01)。沙格列汀組胰島素抵抗指數(shù)(HOMA-IR)[3.25(1.68~6.11)vs 2.88(1.48~5.52)]及高敏C反應(yīng)蛋白(hsC-RP)[1.67(0.51~3.97)vs 1.51(0.44~4.63)mg/L]較治療前降低(P0.05)。結(jié)論沙格列汀在有效控制T2DM伴MONW患者血糖的同時(shí),可降低其BF,減輕IR,改善患者慢性炎癥狀態(tài)。
[Abstract]:Objective to evaluate the efficacy of salgletine combined with metformin in the treatment of T2DM with normal body weight metabolic obesity and its effect on body fat composition. Methods 197 patients with T2DM who received metformin alone for 12 weeks but whose blood glucose was not well controlled were selected. In accordance with the MONW diagnostic criteria, the subjects were divided into two groups according to the random number method: one hundred cases in the salgletine group and 97 cases in the glipizide group. Both groups were treated with metformin for 12 weeks. Results compared with before treatment, HbA_1c in the two groups was lower than that before treatment [salgletine 8.37 鹵0.75 vs 7.25 鹵0.62C, glipizide 8.42 鹵0.78 vs 7.27 鹵0.72P 0.05], the incidence of hypoglycemia in the salgletine group was lower than that in the glipizide group 3.0vs29.9P0.01.The WC of the salgletine group was 85.84 鹵4.07vs84.08 鹵4.53cm-1, and the incidence of hypoglycemia in the salgletine group was lower than that in the glipizide group. After treatment, female patients (81.53 鹵5.93v / s 79.09 鹵4.91cm) and BF [male 28.71 鹵4.22vsl = 27.47 鹵5.66cm, female = 37.18 鹵6.52vsl 36.06 鹵6.30g] decreased P0.055g compared with those before treatment in the salgletine group (86.94 鹵4.20 vs 84.08 鹵4.53 cm, 83.48 鹵5.51 vs 79.09 鹵4.91cm) and BF [30.70 鹵5.72vsl 27.47 鹵5.66g / g, 39.36 鹵7.23svv06 鹵6.306.30%] compared with the Gelatin group (P < 0.01). Conclusion Saglitine can effectively control blood glucose in patients with T2DM with MONW. Can reduce its BF, alleviate IR, improve patient chronic inflammation condition.
【作者單位】： 安徽醫(yī)科大學(xué)附屬省立醫(yī)院 安徽省立醫(yī)院內(nèi)分泌科;
【基金】：安徽省衛(wèi)生廳醫(yī)學(xué)科研課題項(xiàng)目(13zc003)
【分類號(hào)】：R587.1;R589.2

【相似文獻(xiàn)】

相關(guān)期刊論文 前10條

1 陸菊明;;2型糖尿病治療新藥沙格列汀的藥理及臨床評(píng)價(jià)[J];中國(guó)新藥雜志;2011年21期

2 李珊珊;張潔;肖珊;;沙格列汀治療初診伴超重或肥胖的2型糖尿病患者療效觀察[J];實(shí)用糖尿病雜志;2013年03期

3 占美;吳逢波;吳斌;唐堯;;沙格列汀治療糖尿病安全性的系統(tǒng)評(píng)價(jià)[J];中國(guó)醫(yī)院藥學(xué)雜志;2012年12期

4 溫晨東;李興;;沙格列汀治療2型糖尿病的有效性和安全性探討[J];臨床醫(yī)藥實(shí)踐;2013年09期

5 蘇向輝;孫侃;宋學(xué)鋒;常向云;葉芳;王艷麗;;沙格列汀治療老年糖尿病對(duì)肝、腎、心功能的影響[J];中國(guó)老年學(xué)雜志;2013年20期

6 趙文麗;;沙格列汀在治療2型糖尿�、蚱谂R床試驗(yàn)中達(dá)到安全性主終點(diǎn),不增加心血管病死亡危險(xiǎn)[J];國(guó)際藥學(xué)研究雜志;2013年06期

7 張瑩;張浩航;謝毅娟;孟棟棟;陳慧;劉恩;;沙格列汀對(duì)新診斷2型糖尿病患者血清炎癥因子及外周血單個(gè)核細(xì)胞核因子κB活性的影響[J];今日藥學(xué);2013年06期

8 ;研究[J];藥品評(píng)價(jià);2013年19期

9 壽成珉;周旦陽;陳惠萍;劉穎慧;;沙格列汀治療2型糖尿病血糖控制不佳療效及安全性觀察[J];浙江中西醫(yī)結(jié)合雜志;2014年05期

10 占美;徐s，

本文編號(hào)：1623596